YESWEHACK/ATG
1.12.2021 10:02:10 CET | Business Wire | Press release
YesWeHack , Europe’s leading bug bounty platform has partnered with Sweden headquartered ATG , to identify potential vulnerabilities on its exposed assets. ATG provides quality excitement and entertainment through horse betting, sports betting and casino games for approximately 1.4 million customers.
ATG is constantly evolving to meet new technology demands, increased data access, faster connections, and new digital channels. It is at the forefront of using digital technology to offer content-rich, personalised, and constantly available entertainment while meeting stricter regulation, digitalisation, and higher customer demands.
Like other industries that retain extensive customer data, the sports betting and gambling industry is particularly vulnerable to cyber threats. In addition to the games themselves, ATG maintains databases that contain a wealth of private and financial information. It has payment systems and apps that hackers can target. Meanwhile, one of the most significant challenges in the sports betting industry is match-fixing, which is unlawful manipulation of the sports results.
ATG strongly emphasises guarding against cybersecurity threats, especially as mobile and online transactions become the norm. It continuously reviews its offering, having frequently conducted penetration testing in the past. It is now planning to level up its security posture, and the bug bounty program with YesWeHack will play a crucial role in securing its platforms, thus reinforcing the trust of its partners and customers towards the ATG brand.
YesWeHack bug bounty programs offer a modern solution since testing is not limited to a small set of testers. Crowdsourced security will help ATG access a diverse range of security researchers, also called hunters, with unique specialisation and in-depth knowledge of the industry. ATG has started with a private bug bounty program where YesWeHack invited selected researchers to confirm the high level of security of ATG’s platform. This will soon be followed by a public bug bounty program where the platforms will be scrutinised by the entire YesWeHack community, representing more than 30,000 global cybersecurity researchers.
“ATG aims to combine our tradition and values with modern technology to improve and develop the gaming experience constantly,” said Erik Täfvander, Head of Cyber Security at ATG. “Our experience with YesWeHack has been stellar right from the beginning, and we hope to address every conceivable vulnerability on our platform that needs to be taken care of before it is exposed,” he added.
“ATG has a strong focus to create a positive gaming experience and wants to serve as an example for the betting industry,” said Guillaume Vassault-Houlière, CEO and Co-Founder of YesWeHack. “Adopting game-changing technologies such as bug bounty clearly shows that they are ahead of the competition and racing to win the hearts of their customers,” he added.
ATG will share their experience and best tips on how to get the most out of the ethical hackers community in a Webinar on December 7th. For more information: Blog post and Registration
ABOUT YESWEHACK
Founded in 2015, YesWeHack is the #1 European Bug Bounty & VDP Platform. YesWeHack offers companies an innovative approach to cybersecurity with Bug Bounty (pay-per-vulnerability discovered), connecting more than 30,000 cybersecurity experts (ethical hackers) across 170 countries with organizations to secure their exposed scopes and reporting vulnerabilities in their websites, mobile apps, infrastructure and connected devices. YesWeHack runs private and public programs for hundreds of organizations worldwide in compliance with the strictest European regulations.
In addition to the Bug Bounty platform, YesWeHack also offers: a creation and management solution for Vulnerability Disclosure Policy (VDP), a learning platform for ethical hackers called Dojo and a training platform for educational institutions, YesWeHackEDU. For more information: www.yeswehack.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom